- Trial Phase
- Phase 2a/2b (dosing initiated ~July 27, 2026); Phase 1 SAD in thyroid eye disease previously reported
- Time to Market
- Unknown — mid-stage. If the Phase 2a/2b trial succeeds and later registrational studies follow, approval would be several years away (late 2020s at the earliest); the company currently has no approved products.
- Why 5/10
- The single next hard catalyst is the Phase 2a/2b proof-of-concept readout for Graves' disease, guided for 2H 2027 — roughly 11-17 months out with no precise date — so it falls outside the "dated binary within ~6-12 months" bands, capping the score at 5 even though this one asset is essentially the entire thesis of the merged company.
YB-101 is a Phase 2a/2b, single-asset bet at a company (Nasdaq: YARW, formerly VYNE) that just closed a reverse merger, raised ~$200M, and began dosing the pivotal-to-next-stage trial — but the defining data readout is not expected until 2H 2027. A non-medical investor should treat YARW as a speculative, liquidity-thin clinical stock: watch for interim Phase 2a/2b data, the exact readout date, and any competitive readouts from anti-FcRn/IgG-degrading drugs in Graves'/thyroid eye disease.
Price Chart
Executive Summary
YB-101 is the lead and essentially only clinical asset of Yarrow Bioscience (Nasdaq: YARW), formed when private Yarrow reverse-merged into VYNE Therapeutics in late July 2026 (VYNE shareholders ended up with ~3% of the combined company, which raised ~$200M and has runway into 2028). It is a potential first-in-class anti-TSHR antibody with FDA Fast Track designation for Graves' disease; a Phase 2a/2b trial began dosing at the merger close, with proof-of-concept data guided for 2H 2027. The bull case rests on a differentiated mechanism, an encouraging early Phase 1 signal and a long cash runway; the bear case is that this is a single-asset, no-revenue company whose one meaningful binary is roughly a year away, facing competition from anti-FcRn/IgG-degrading biologics in the same space.
How It Works
YB-101 is an injected antibody that blocks the thyroid-stimulating hormone receptor (TSHR) — the cellular "on switch" that Graves' disease antibodies wrongly activate. In Graves' disease that overstimulation drives excess thyroid hormone; in thyroid eye disease it fuels inflammation and swelling of tissue behind the eyes. By blocking the receptor, YB-101 aims to stop the disease at its source rather than just treating symptoms.
Trial Status
Dosing in the Phase 2a/2b Graves' disease trial was initiated around the July 27, 2026 merger close, per the company's announcement. Yarrow's investor presentation (filed with SEC July 14, 2026) cites a prior Phase 1 single-ascending-dose study in thyroid eye disease with no SAEs, no hearing or hyperglycemia adverse events, and dose-dependent proof of mechanism (66.7% ORR with proptosis improvement vs 10-20% placebo). Phase 2a proof-of-concept data are guided for 2H 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 2a/2b Graves' disease trial interim/updates as enrollment proceeds (no dates announced)
- Phase 2a proof-of-concept data readout, guided 2H 2027 — the main stock-moving event
- Any announcement of the precise readout date, regulatory updates, or competitive readouts in Graves'/thyroid eye disease
- Quarterly filings and cash-runway updates from the newly merged YARW
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VYNE Therapeutics Inc. 425 VYNE ·Originating report